caa a22 4500 465789633 CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900801xx s 000 0 eng 10.1007/BF00171839 doi (NATIONALLICENCE)springer-10.1007/BF00171839 Phase II Studies [Elektronische Daten] [M. Kennedy, Ross Donehower, Louise Grochow, David Ettinger, John Fetting, Martin Abeloff] Summary: Eighteen women with metastatic breast cancer previously untreated with chemotherapy were entered on a phase II trial of intravenous menogaril, a new anthracycline derivative. Treatment was given at 140 mg/m2 on days 1 and 8 of each 28 day cycle. The most common toxicities were leukopenia in all patients and burning and phlebitis at infusion sites in 72%. Serial assessment of cardiac function by resting and stress gated blood pool scans showed temporary decrements in ejection fraction in only 2 patients (11%). The response rate to the therapy was 19% [95% CI 0-38%] including 1 complete and 2 partial responses. The median time to relapse among responders was 6.5 months. Mean survival in all patients entered was 15.8 months from date of entry. Menogaril at this dose and schedule has modest activity as first line therapy for metastatic breast cancer but also has significant marrow and local toxicity. Kluwer Academic Publishers, 1990 menogaril nationallicence phase II nationallicence breast cancer nationallicence Kennedy M. The Johns Hopkins Oncology Center, Baltimore, MD aut Donehower Ross The Johns Hopkins Oncology Center, Baltimore, MD aut Grochow Louise The Johns Hopkins Oncology Center, Baltimore, MD aut Ettinger David The Johns Hopkins Oncology Center, Baltimore, MD aut Fetting John The Johns Hopkins Oncology Center, Baltimore, MD aut Abeloff Martin The Johns Hopkins Oncology Center, Baltimore, MD aut Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 289-294 0167-6997 8:3<289 1990 8 10637 https://doi.org/10.1007/BF00171839 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171839 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kennedy M. The Johns Hopkins Oncology Center, Baltimore, MD aut NATIONALLICENCE 700 1- Donehower Ross The Johns Hopkins Oncology Center, Baltimore, MD aut NATIONALLICENCE 700 1- Grochow Louise The Johns Hopkins Oncology Center, Baltimore, MD aut NATIONALLICENCE 700 1- Ettinger David The Johns Hopkins Oncology Center, Baltimore, MD aut NATIONALLICENCE 700 1- Fetting John The Johns Hopkins Oncology Center, Baltimore, MD aut NATIONALLICENCE 700 1- Abeloff Martin The Johns Hopkins Oncology Center, Baltimore, MD aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 289-294 0167-6997 8:3<289 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer